Polymyalgia rheumatica: concerted efforts of the European rheumatological societies


  • О.G. Puzanova Kyiv Medical University, Kyiv, Ukraine http://orcid.org/0000-0002-4451-659X
  • Yu.О. Moshkovska Bogomolets National Medical University, Kyiv, Ukraine
  • V.О. Sobol Bogomolets National Medical University, Kyiv, Ukraine




polymyalgia rheumatica, treatment, standards, review


Population’s ageing is a prerequisite for a strengthened evidence base of the specific geriatric syndromes, late-onset rheumatic diseases, and rheumatic diseases of the elderly. Among the latter, the most common is polymyalgia rheumatic whose presence and management are associated with the issues of tolerance to ­analgesics and anti-inflammatory medications and timely diagnosis of giant cell arteritis and malignancies. In Europe, namely in the German-speaking countries, there is a significant heterogeneity in the approaches to the polymyalgia rheumatica management persisting in the clinical practice. That is why the guidelines of the German Society of Rheumatology, the Austrian Society of Rheumatology and Rehabilitation, the Swiss Society of Rheumatology, and participa­ting expert medical-research societies and other organizations del­ving in this problem, were elaborated and published in 2018. Its evi­dence base, overarching principles and specific recommendations are presented and discussed in the article. The guidelines are compared with the 2015 European League Against Rheumatism’s and the American College of Rheumatology’s recommendations for the management of polymyalgia rheumatica, and the Finnish Medical Association’s guidelines recommended by the Ministry of Health of Ukraine for use in primary care as a new clinical protocol in 2016.


Download data is not yet available.


Beketova TV, Satybaldyev AM, Denisov LN. International guidelines for the management of giant cell arteritis and polymyalgia rheumatica: The 2015 results. Rheumatology Science and Practice. 2016;54(4):390-394. https://doi.org/10.14412/1995-4484-2016-390-394. (in Russian).

Golovach IYu. Basic principles of new diagnostic criteria (2012) and recommendations of the ACR/EULAR 2015 on management and treatment of rheumatic polymyalgia. Ukrainian Journal of Rheumatology. 2016;(64):3-7. (in Russian).

Satybaldyev AM. The evolution of diagnosis of polymyalgia rheumatica. Rheumatology Science and Practice. 2019;57(6):693-698. https://doi.org/10.14412/1995-4484-2019-693-698. (in Russian).

Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484-492. http://dx.doi.org/10.1136/annrheumdis-2011-200329.

Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799-1807. http://dx.doi.org/10.1136/annrheumdis-2015-207492.

Buttgereit F, Brabant T, Dinges H, et al. S3 guidelines on treatment of polymyalgia rheumatica : Evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol. 2018;77(5):429-441. https://doi.org/10.1007/s00393-018-0476-8. (in German).

Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA. 2016;315(22):2442-2458. https://doi.org/10.1001/jama.2016.5444.

Dejaco C, Matteson EL, Buttgereit F. Diagnostics and treatment of polymyalgia rheumatica. Z Rheumatol. 2016;75(7):687-700. https://doi.org/10.1007/s00393-016-0105-3. (in German).

Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506-515. https://doi.org/10.1093/rheumatology/kew273.

Hellmich B. Management of polymyalgia rheumatica and large vessel vasculitis. Internist (Berl). 2016;57(11):1069-1078. https://doi.org/10.1007/s00108-016-0131-x. (in German).

Leung JL, Owen CE, Buchanan RRC, Liew DFL. Management of polymyalgia rheumatica. J Pharm Pract Res. 2019;49(5):493-500. https://doi.org/10.1002/jppr.1610.

Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1-e23. https://doi.org/10.1093/rheumatology/kez672.

Matteson EL, Buttgereit F, Dejaco C, Dasgupta B. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. Rheum Dis Clin North Am. 2016;42(1):75-viii. https://doi.org/10.1016/j.rdc.2015.08.009.

Matteson EL, Dejaco C. Polymyalgia Rheumatica. Ann Intern Med. 2017;166(9):ITC65-ITC80. https://doi.org/10.7326/aitc201705020.

Muratore F, Pazzola G, Pipitone N, Salvarani C. Recent advances in the diagnosis and treatment of polymyalgia rheumatica. Expert Rev Clin Immunol. 2016;12(10):1037-1045. https://doi.org/10.1080/1744666X.2016.1178572.

Yurdakul FG, Bodur H, Sivas F, Baskan B, Eser F, Yilmaz O. Clinical features, treatment and monitoring in patients with polymyalgia rheumatica. Arch Rheumatol. 2015;30(1):28-33. https://doi.org/10.5606/ArchRheumatol.2015.4643.

Moskalenko VF, Puzanova OG. Implementation of the program of national clinical guidelines development in Germany. Naukovij visnik Nacionalʹnogo medičnogo universitetu imeni OO Bogomolʹcâ. 2010;2(29);48-55. (in Ukrainian).

Lally L, Forbess L, Hatzis C, Spiera R. Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica. Arthritis Rheumatol. 2016;68(10):2550-2554. https://doi.org/10.1002/art.39740.

Hancock AT, Mallen CD, Muller S, et al. Risk of vascular events in patients with polymyalgia rheumatica. CMAJ. 2014;186(13):E495-E501. https://doi.org/10.1503/cmaj.140266.

Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I. A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer. J Clin Rheumatol. 1996;2(6):305-308. https://doi.org/10.1097/00124743-199612000-00002.

Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Arch Intern Med. 1997;157(20):2381.

Bellan M, Boggio E, Sola D, et al. Association between rheumatic diseases and cancer: results from a clinical practice cohort study. Intern Emerg Med. 2017;12(5):621-627. https://doi.org/10.1007/s11739-017-1626-8.

Dasgupta B, Dolan AL, Panayi GS, Fernandes L. An initially double-blind controlled 96 week trial of depot methylprednisolone against oral prednisolone in the treatment of polymyalgia rheumatica. Br J Rheumatol. 1998;37(2):189-195. https://doi.org/10.1093/rheumatology/37.2.189.

Cutolo M, Hopp M, Liebscher S, Dasgupta B, Buttgereit F. Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. RMD Open. 2017;3(1):e000426. https://doi.org/10.1136/rmdopen-2016-000426.

Van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69(11):1913-1919. https://doi.org/10.1136/ard.2009.124958.

Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543-546. https://doi.org/10.1136/annrheumdis-2016-210002.

Dachverband Osteologie (DVO). DVO guidelines 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie. 2011;20(1):55-74. https://doi.org/10.1055/s-0037-1619980.

Dachverband Osteologie (DVO). Prophylaxe, Diagnostik und Therapie der Osteoporose bei Männern ab dem 60 Lebensjahr und bei postmenopausalen Frauen: S3-Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e.V. Bad Vilbel: DVO; 2014. (in German).

Ayoub WT, Franklin CM, Torretti D. Polymyalgia rheumatica. Duration of therapy and long-term outcome. Am J Med. 1985;79(3):309-315. https://doi.org/10.1016/0002-9343(85)90309-2.

Cimmino MA, Parodi M, Caporali R, Montecucco C. Is the course of steroid-treated polymyalgia rheumatica more severe in women?. Ann N Y Acad Sci. 2006;1069:315-321. https://doi.org/10.1196/annals.1351.030.

Barraclough K, Liddell WG, du Toit J, et al. Polymyalgia rheumatica in primary care: a cohort study of the diagnostic criteria and outcome. Fam Pract. 2008;25(5):328-333. https://doi.org/10.1093/fampra/cmn044.

Cantini F, Salvarani C, Olivieri I, et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum. 2000;30(1):17-24. https://doi.org/10.1053/sarh.2000.8366.

González-Gay MA, Rodríguez-Valverde V, Blanco R, et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med. 1997;157(3):317-320. https://doi.org/10.1001/archinte.1997.00440240081012.

Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65-73.

Lee JH, Choi ST, Kim JS, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33(6):1475-1480. https://doi.org/10.1007/s00296-012-2580-4.

Myklebust G, Gran JT. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients. Scand J Rheumatol. 2001;30(5):260-267. https://doi.org/10.1080/030097401753180327.

Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum. 1998;41(7):1221-1226. https://doi.org/10.1002/1529-0131(199807)41:7%3C1221::aid-art12%3E3.0.co;2-w.

Ministry of Нealth of Ukraine. Order on September 28, 2012 № 751. On Development and Implementation of Medical and Technological Documents for the Standardization of Medical Care in the System of the Ministry of Health of Ukraine. Available from: https://zakon.rada.gov.ua/laws/show/z2001-12#Text. Accessed: September 28, 2012. (in Ukrainian).

Ministry of Нealth of Ukraine; Finnish Medical Society DUODECIM. Guideline 01095. Polymyalgia Rheumatica. Available from: https://guidelines.moz.gov.ua/documents/3811/. Accessed: 14.03.2020. (in Ukrainian).




How to Cite

Puzanova О., Moshkovska, Y., & Sobol, V. (2021). Polymyalgia rheumatica: concerted efforts of the European rheumatological societies. PAIN, JOINTS, SPINE, 10(3), 118–126. https://doi.org/10.22141/2224-1507.10.3.2020.212033